Active surveillance for low-risk prostate cancer

详细信息    查看全文

• 作者：Chris H. Bangma^a ; ^{h.j.vanalphen@erasmusmc.nl}Author Vitae ; Meelan Bul^a ; Theo H. van der Kwast^c ; Tom Pickles^e ; Ida J. Korfage^b ; Caroline M. Hoeks^f ; Ewout W. Steyerberg^b ; Guido Jenster^a ; Michael W. Kattan^g ; Lara Bellardita^d ; Peter R. Carroll^h ; Louis J. Denisⁱ ; Chris Parker^j ; Monique J. Roobol^a ; Mark Emberton^k ; Laurence H. Klotz^l ; Antti Rannikko^m ; Yoshiyuki Kakehiⁿ ; Janet A. Lane^o ; Fritz H. Schrö ; der^a ; Axel Semjonow^p ; Bruce J. Trock^q ; Riccardo Valdagni^d
• 关键词：AS ; active surveillance ; PCa ; prostate cancer ; PSA ; prostate-specific antigen ; ERSPC ; European Randomized Study of Screening for Prostate Cancer ; QALY ; quality adjusted life years ; QOL ; quality of life ; PRIAS ; Prostate Cancer Research International ; Activ
• 刊名：Critical Reviews in Oncology/Hematology
• 出版年：2013
• 出版时间：March, 2013
• 年：2013
• 卷：85
• 期：3
• 页码：295-302
• 全文大小：138 K

文摘

Active surveillance (AS) is an important management strategy for men diagnosed with low-risk prostate cancer (PCa). The need for AS is increasing due to the awareness that many PCa are identified that show a low growth potential and therefore are likely to remain clinically asymptomatic during the lifetime of an individual. Currently there is no good method to prevent the overdiagnosis of indolent cancers upfront. During the last decade, several studies on AS around the world have made observations that feed the discussion on how to select and monitor these patients, how to proceed with the research to develop a better and more precise clinical definition of indolent cancers and how to manage men under AS clinically. Furthermore, patients¡¯ perspectives have become clearer, and quality of life studies give direction to the practical approach and care for patients and partners. This paper reflects the consensus on the state of the art and the future direction of AS, based on the Inside Track Conference ¡°Active Surveillance for low risk prostate cancer¡± (Chairmen: C.H. Bangma, NL, and L. Klotz, CA; Co-Chairmen: L.J. Denis, BE, and C. Parker, UK; Scientific Coordinators: M. J. Roobol, NL, and E.W. Steyerberg, NL), organized by the European School of Oncology in collaboration with Europa Uomo in Rotterdam, the Netherlands in January 2012. Topics for discussion were the optimisation of patient selection based on indolent disease definition, the incorporation of therapeutic agents into AS programs, the optimisation of patient care, and the application of emerging technologies and biomarkers.